VySpine Announces FDA Clearances for VySpan, VyLam and VySpine Innovations

Trio of Clearances Expands VySpine’s Growing Product Portfolio

VySpine, a spine innovation leader using differentiated materials and designs, announced today that it has received a trio of U.S. Food and Drug Administration (FDA) clearances for its products, providing increased diversity to the company’s portfolio.

Among the approvals announced is FDA clearance for additional connectors for the VySpan PCT system to add to its versatility. These new, robust connectors can be easily attached to the VyLink Screw System.

VySpine also received a 510(k) clearance from the FDA for its VyLam System, which is indicated for use in laminoplasty of the lower cervical and upper thoracic spine (C3-T3) in skeletally mature patients.

In addition, the FDA has approved additional indications for VySpine’s VyLink Screw System. The VyLink Screw, when used in the sacroiliac joint, is intended for the emerging market of sacroiliac joint fusion, allowing surgeons to provide an alternative way to treat patients with sacroiliac joint dysfunction.

“Receiving this series of three FDA clearances in quick succession not only marks a major step in our company’s development,” said Bret Berry, VySpine’s President of Product Development, “it also helps bring a heightened level of flexibility to the spine surgery community. Using new materials and creative surgeon input, we also continue to build exceptional quality and pricing into all our products. This is the just the beginning of the exciting, innovative product launches we have scheduled for early 2024.”

 

SourceVySpine
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with "GPS-like" guidance with millimetric accuracy in real-time. Zeta's computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings.
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

By using this website you agree to accept Medical Device News Magazine Privacy Policy